Summary of Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2018

Accounting Policies [Abstract]

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share

The following common share equivalents were excluded from the computation of diluted net income (loss) per common share for the periods presented because including them would have been antidilutive (in thousands):

	Year Ended December 31,
	2018		2017
Stock options and restricted stock units		14,269		7,983
Warrants		-		9,395
Treasury stock		-		81

Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the consolidated balance sheet dates that comprise the total of the same such amounts shown in the consolidated statements of cash flows for all periods presented herein and effected by the adoption of ASU 2016-18 (in thousands):

	December 31,
	2018		2017		2016
Cash and cash equivalents	$	23,587	$	36,838	$	22,088
Restricted cash included in prepaid expenses and other current assets (see Note 15)		346		-		-
Restricted cash included in deposits and other long-term assets (see Note 15)		466		847		847
Total cash, cash equivalents, and restricted cash as shown in the consolidated statements of cash flows	$	24,399	$	37,685	$	22,935

Schedule of Disaggregated Revenues

The following table presents BioTime’s consolidated revenues disaggregated by source (in thousands).

	Year Ended December 31,
REVENUES:	2018		2017 (1)
Grant revenue	$	3,572	$	1,666
Royalties from product sales and license fees		392		389
Subscription and advertisement revenues (2)		691		1,395
Sale of research products and services		333		8
Total revenues	$	4,988	$	3,458

(1)

Amounts recognized prior to adoption of Topic 606 have not been adjusted under the Topic 606 modified retrospective transition method.

(2)

These revenues were generated by LifeMap Sciences, which is a subsidiary of AgeX, are included in BioTime consolidated revenues for the period from January 1, 2018 through August 29, 2018, the date immediately preceding the AgeX Deconsolidation. As a result of the AgeX Deconsolidation on August 30, 2018, BioTime does not expect to recognize subscription and advertisement revenues during subsequent accounting periods.

Schedule of Disaggregated by Geographical Revenue

The following table presents consolidated revenues, disaggregated by geography, based on the billing addresses of customers, or in the case of grant revenues based on where the governmental entities that fund the grant are located (in thousands). See further discussion under Grant Revenues below.

	Year Ended December 31,
REVENUES:	2018		2017 (1)
United States	$	1,804	$	1,651
Foreign (2)		3,184		1,807
Total revenues	$	4,988	$	3,458

(1)	Amounts recognized prior to adoption of Topic 606 have not been adjusted under the Topic 606 modified retrospective transition method.
(2)	Foreign revenues are primarily generated from grants in Israel.